Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- The purpose of this study was to assess the potential systemic toxicity in rats, including a screen for reproductive/developmental effects and assessment of endocrine disruptor relevant endpoints, with administration of Amidoamine (UVCB) by oral gavage administration for at least five weeks.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Triglycerides, C16-18 (even numbered), reaction products with diethylenetriamine
- Molecular formula:
- not applicable (UVCB)
- IUPAC Name:
- Triglycerides, C16-18 (even numbered), reaction products with diethylenetriamine
- Test material form:
- solid: compact
- Details on test material:
- - Name of test material (as cited in study report): Amidoamine (UVCB)
- Substance type: Amidoamine
- Chemical name: Glycerides, C14-20, reaction products with diethylenetriamine (preliminary naming)/Amides, from diethylenetriamine and hydrogenated palm oil
- CAS 85409-11-6/1618093-67-6
- Physical state: pale yellowish solid at 20 °C
- Batch No.: K8 4309 L481
- Expiry date of batch: 09 March 2017
- Purity: 100 % (UVCB)
- Storage condition of test material: Room temperature, protected from light
- Stability: stable under test conditions
Constituent 1
- Specific details on test material used for the study:
- Test item without emulsifier was investigated.
Amidoamine (UVCB)
Pulcra ID: DE07_2014_012_BEL66 (amidoamine without emulsifier)
Physical state: pale yellowish solid at 20 °C
Batch No.: K8 4309 L481
Expiry date of batch: 09 March 2018
Purity: 100 % (UVCB)
Stability: stable under test conditions
Storage condition of test material: Room temperature, protected from light
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- Test animals
The rat was chosen as the test species because of the requirement for a rodent species by regulatory agencies. The RccHan;WIST (Han Wistar) strain was used because of the historical control data available at this laboratory.
Strain/Species: RccHan™;WIST rat.
Supplier: Envigo (RMS) B.V.
Number of animals ordered: 44 males and 48 females.
Duration of acclimatization Males: five days prior to the commencement of treatment.
Duration of acclimatization Females: 19 days prior to the commencement of treatment.
Age of the animals at the start of treatment Males: nominally 12 weeks old.
Age of the animals at the start of treatment Females: nominally 14 weeks old.
Weight range of the animals at the start of treatment Males: 325 to 356 g.
Weight range of the animals at the start of treatment Females: 202 to 252 g.
Environmental conditions
Rodent facility: Limited access - to minimize entry of external biological and chemical agents and to minimize the transference of such agents between rooms.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1% methylcellulose in 0.1% Tween 80
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- An analytical methods was developed to quantify Amidoamine (UVCB) or Amidoamine 2 (UVCB, low nitrogen content) in liquid vehicle at concentrations from 1 – 200 mg/mL (approximately). The homogeneity and stability of Amidoamine (UVCB) formulations during storage were determined as part of another study, Envigo Study Number TD87XR. Stability was confirmed for 15 days when stored refrigerated (2 to 8 °C) and for one day when stored at ambient temperature (15 to 25 °C) between the concentration range 5 to 200 mg/mL.
- Details on mating procedure:
- Pairing commenced: After a minimum of two weeks of treatment.
Male/female ratio: 1:1 from within the same treatment groups.
Duration of pairing: Up to two weeks.
Daily checks for evidence of mating: Ejected copulation plugs in cage tray and sperm in the vaginal smear.
Day 0 of gestation: When positive evidence of mating was detected.
Male/female separation: Day when mating evidence was detected.
Pre-coital interval: Calculated for each female as the time between first pairing and evidence of mating. - Duration of treatment / exposure:
- Males: Two weeks before pairing up to necropsy after a minimum of five weeks of treatment.
Females: Two weeks before pairing, then throughout pairing and gestation until Day 13 of lactation. Two females were also treated on Day 14 of lactation - Frequency of treatment:
- Once daily at approximately the same time each day.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 330 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- No. of animals per sex per dose:
- 10 animals of each sex per dose.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection rationale:
The dose levels have been selected in agreement with the Sponsor based on the results of a 14-day dose-range-finding study in rats dosed at 100, 300 and 1000 mg (active ingredient)/kg bw by oral gavage (Envigo Study No. YT38XB).
No animals died prematurely. Oral treatment with 1000 mg/kg bw/day caused no signs of systemic toxicity.
In that study Amidoamine (UVCB) or Amidoamine 2 (UVCB, low nitrogen content) were administered to rats at doses of 100 or 1000 mg/kg/day, there were no clear effects of treatment from either test item on body weight, food consumption, water consumption, organ weights or tissue appearance at necropsy. Therefore the test material of Amidoamine (UVCB) was selected for this study. The high dose of 1000 mg/kg/day is the limit dose for the OECD 422 study guideline and the intermediate and low doses of 330 and 100 mg/kg/day were selected to investigate any dose relationship should effects be observed in the longer duration study.
Examinations
- Statistics:
- Statistical analyses were performed on the majority of data presented and results of these tests, whether significant or non-significant. For some parameters, including estrous cycles before treatment, pre-coital interval, mating performance, gestation index and stage of estrous cycle at termination the similarity of the data was such that analyses were not considered to be necessary. All statistical analyses were carried out separately for males and females using the individual animal as the basic experimental unit. For litter/fetal findings the litter was taken as the treated unit and the basis for statistical analysis and biological significance was assessed with relevance to the severity of the anomaly and the incidence of the finding within the background control population.
The following data types were analyzed at each timepoint separately:
Grip strength and motor activity
Body weight, using absolute weights and gains over appropriate study periods
Food consumption, over appropriate study periods during gestation and lactation
Hematology, blood chemistry and urinalysis
Estrous cycles during treatment
Gestation length
Ano-genital distance, adjusted for pup body weight
Litter (implantations, litter size, sex ratio - percentage male, post implantation survival index, live birth index and viability index), for before blood sampling study periods
Organ weights, both absolute and adjusted for terminal body weight
A sequence of statistical tests was used for inter alia grip strength, motor activity, body weight, food consumption, implantations, litter size, sex ratio - percentage male, post implantation survival index, ano-genital distance, organ weight and clinical pathology data-
A parametric analysis was performed if Bartlett's test for variance homogeneity (Bartlett 1937) was not significant at the 1% level.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- The clinical condition of the animals, their behavior in the arena, sensory reactivity, grip strength, motor activity, body weight gain and food intake were all unaffected by treatment and no treatment-related abnormalities were identified histopathologically.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No premature deaths occurred during the study.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Overall group mean body weight gain was considered unaffected by treatment. In females before pairing, body weight gain was high, when compared with the controls at all doses levels (50, 48 and 99% higher than control, respectively) however, during gestation and lactation body weight gain was similar to controls. It was therefore, considered that this was fortuitous and unrelated to treatment.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment upon food intake.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The hematological examination of peripheral blood performed at termination revealed, when compared with controls, a slight increase in neutrophil, lymphocyte and monocyte counts (with a consequential increase of total leucocyte count) among females receiving 100, 330 or 1000 mg/kg/day, generally attaining statistical significance at all dose levels for lymphocyte, monocyte and total leucocyte counts. A similar effect was seen in males (neutrophils and monocyte counts only). In the absence of a clear dose-response and a high individual value in a single male (No.14) a relationship to treatment is unclear.
All inter-group differences from control, including those attaining statistical significance, were minor, lacked dose-relationship or were confined to one sex and were therefore attributed to normal biological variation. Such differences included the low group mean prothrombin time at all doses in females, but this was a consequence of the high control group mean value that was partly due to a particularly high value for one animal (Animal No. 47; 30.1 seconds). - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The biochemical examination of plasma performed at termination did not reveal any changes that were clearly related to treatment with Amidoamine (UVCB).
All inter-group differences from control, including those attaining statistical significance, were minor, lacked dose-relationship or were confined to one sex and were therefore attributed to normal biological variation. Such differences included the slightly low plasma urea concentrations in males given 1000 mg/kg/day, but the individual differences from control were slight, and there was no similar effect observed in the females. Plasma glucose concentrations were marginally, but statistically significantly low, in males at all dose levels, but there was no dose-relationship, and the majority of individual values were similar to the controls. There were a few statistically significant differences from control among the plasma electrolytes (sodium and potassium in males and chloride in females) but there was no dose-relationship in any of the affected parameters and the urinalysis investigations did not reveal any effect on the urinary output of electrolytes. Plasma bile acid concentrations were statistically significantly low in males at all dose levels, but there no clear dose-relationship and the individual values were highly variable. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The urinalysis investigations performed at termination did not identify any treatment-related changes. All inter-group differences from control, including those attaining statistical significance, were minor, lacked dose-relationship or were confined to one sex and were therefore attributed to normal biological variation. Such differences included the marginally, but statistically significantly, low pH in males receiving 1000 mg/kg/day, where the difference form control was minor and the individual values were similar to the controls.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- There were no signs seen at the routine examination that were considered to be related to treatment with Amidoamine and no premature deaths occurred during the study.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no histopathological correlate for the slightly low heart weights in males given 330 or 1000 mg/kg/day or the low liver weights in males given 1000 mg/kg/day, and no similar changes were observed in the females, therefore these changes were considered to be fortuitous and of no consequence.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no signs seen at the routine examination that were considered to be related to treatment with Amidoamine and no premature deaths occurred during the study
- Neuropathological findings:
- no effects observed
- Description (incidence and severity):
- There were no signs seen at the routine examination that were considered to be related to treatment with Amidoamine and no premature deaths occurred during the study.
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No changes related to treatment with Amidoamine (UVCB) were seen.
There were no test item-related microscopic findings in the testes, following the qualitative examination of the stages of spermatogenesis (no test item-related abnormalities were identified in the integrity of the various cell types present within the different stages of the sperm cycle) or following the evaluation of the uterus or of the follicles and corpora lutea in the ovaries. The incidence and distribution of all findings were considered to be unrelated to treatment.
Pathology procedures for the five lowest numbered surviving males and females with a surviving litter per group at scheduled termination.
- The following organs or parts of organs of all adult animals were fixed in 10% Neutral Buffered Formalin; testes and epididymides were fixed in modified Davidson's fluid/Davidson's fluid:
Abnormalities, cowper's gland, epididymis (2, caput, corpus and cauda), glans penis, levator Ani plus Bulbo Cavernosus (LABC) muscle complex, skin with mammary gland, ovaries (2), prostate, seminal vesicles with coagulating glands, testes (2), thyroids, uterus (incl. cervix and oviducts), vagina.
For the assessment of the testes, a detailed qualitative examination was made, taking into account the tubular stages of the spermatogenic cycle. The examination was conducted in order to identify treatment related effects such as missing germ cell layers or types, retained spermatids, multinucleate or apoptotic germ cells and sloughing of spermatogenic cells in the lumen. Any cell- or stage-specificity of testicular findings was noted.
-In addition, the following organs or parts of organs of the selected 20 adult males and 20 adult females (see section above) were fixed in 10% formalin:
Abnormalities
Adrenal gland (2)
Bone marrow (os femoris)
Brain (cerebrum, cerebellum, pons)
Eyes
Heart (including auricular and ventricular regions)
Intestine, small (duodenum, jejunum, ileum, incl. Peyer's patches)
Intestine, large (colon, rectum)
Kidney and ureter (2)
Liver (section from 2 lobes)
Lungs (section from two major lobes incl. bronchi)
Lymph node (1, left acillary), Lymph node (1, mesenteric)
Nerve (sciatic)
Peyer’s Patch
Pituitary
Skeletal muscle
Sklin with mammary gland
Spinal cord (transverse and longitudinal sections at the cervical level)
Spleen
Sternum (with marrow)
Stomach
Trachea
Thyroid (incl. parathyroids)
Thymus
Urinary bladder - Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no signs seen at the routine examination that were considered to be related to treatment with Amidoamine and no premature deaths occurred during the study.
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no signs seen at the routine examination that were considered to be related to treatment with Amidoamine and no premature deaths occurred during the study.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- not examined
- Total litter losses by resorption:
- not examined
- Early or late resorptions:
- not examined
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- All females allocated to study showed normal 4/5 day estrous cycles during the acclimatization period.
Estrous cyclicity, pre-coital interval, gestation length and index, mating performance and fertility were considered unaffected by treatment with Amidoamine (UVCB). All females showed diestrus at termination.
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.DescriptionIncidenceAndSeverityEffectsOnPregnancyDuration): All females allocated to study showed normal 4/5 day estrous cycles during the acclimatization period.
Estrous cyclicity, pre-coital interval, gestation length and index, mating performance and fertility were considered unaffected by treatment with Amidoamine (UVCB). All females showed diestrus at termination. - Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- All females allocated to study showed normal 4/5 day estrous cycles during the acclimatization period.
Estrous cyclicity, pre-coital interval, gestation length and index, mating performance and fertility were considered unaffected by treatment with Amidoamine (UVCB).
All females showed diestrus at termination - Other effects:
- no effects observed
- Details on maternal toxic effects:
- All females allocated to study showed normal 4/5 day estrous cycles during the acclimatization period.
Estrous cyclicity, pre-coital interval, gestation length and index, mating performance and fertility were considered unaffected by treatment with Amidoamine (UVCB). All females showed diestrus at termination.
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat. (total fraction)
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- dead fetuses
- effects on pregnancy duration
- gross pathology
- haematology
- histopathology: neoplastic
- histopathology: non-neoplastic
- maternal abnormalities
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
- urinalysis
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- not examined
- Description (incidence and severity):
- There was no effect of parental treatment upon offspring group mean body weight gain.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.DescriptionIncidenceAndSeverityFetalPupBodyWeightChanges): There was no effect of parental treatment upon offspring group mean body weight gain. - Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- All females were pregnant and had a live litter on Day 13 of lactation. Litter size, offspring survival to Day 13 of age and sex ratio were unaffected by parental treatment with Amidoamine (UVCB).
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- All females were pregnant and had a live litter on Day 13 of lactation. Litter size, offspring survival to Day 13 of age and sex ratio were unaffected by parental treatment with Amidoamine (UVCB).
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- The clinical condition, litter size, sex ratio, survival indices and body weight gain of offspring were unaffected by parental treatment.
- Changes in postnatal survival:
- no effects observed
- Description (incidence and severity):
- The clinical condition, litter size, sex ratio, survival indices and body weight gain of offspring were unaffected by parental treatment.
- External malformations:
- no effects observed
- Description (incidence and severity):
- The macroscopic examination of offspring revealed no test item related lesions.
The ano-genital distances of offspring were unaffected by parental treatment. - Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- The macroscopic examination of offspring revealed no test item related lesions.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- The macroscopic examination of offspring revealed no test item related lesions.
- Other effects:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on the circulating levels of thyroxine (T4) in adult males or in offspring on Day 13 of age.
The group mean T4 concentration for female offspring on Day 13 of age derived from F0 parents treated at 1000 mg/kg/day was marginally high, when compared with controls, but all individual values were below the highest control value and in both the control group and the high dose group, three individual offspring had T4 levels greater than 60000 pg/mL.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat. (total fraction)
- Sex:
- male/female
- Basis for effect level:
- changes in litter size and weights
- changes in postnatal survival
- external malformations
- skeletal malformations
- visceral malformations
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- It was concluded that the oral administration of Amidoamine (UVCB) to parental Han Wistar rats at dose levels of 100, 330 or 1000 mg/kg/day for two weeks before pairing, during pairing and then up to termination of the males after five weeks of treatment and females on Day 14 of lactation was well tolerated, with no adverse effect of treatment identified. Reproductive performance, fertility, litter size and offspring survival and growth were unaffected by parental treatment and, in the context of this study, Amidoamine (UVCB) showed no evidence of being an endocrine disruptor. The no-observed-adverse-effect level (NOAEL) of Amidoamine (UVCB) for systemic toxicity and also for reproductive/developmental toxicity was considered to be 1000 mg/kg/day.
- Executive summary:
The aim of the study was to obtain information on possible effects of the test item on general toxicity, reproduction and/or development according to OECD guideline 422.
The oral administration of Amidoamine (UVCB) to parental Han Wistar rats at dose levels of 100, 330 or 1000 mg/kg/day for two weeks before pairing, during pairing and then up to termination of the males after five weeks of treatment and females on Day 14 of lactation was well tolerated, with no premature deaths. The clinical condition of the animals, their behavior in the arena, sensory reactivity, grip strength, motor activity, body weight gain and food intake were all unaffected by treatment and no treatment-related abnormalities were identified histopathologically.
In this study there were some inter-group differences from controls that attained statistical significance, particularly at the hematological investigation, where there were some minor differences from controls in respect of the cellular components of the peripheral blood. There were minor increases of neutrophil, lymphocyte and monocyte counts in females receiving 100, 330 or 1000 mg/kg/day with a similar effect seen upon the neutrophil and monocyte counts of males at these dose levels. In view of the minimal extent of the differences from controls, the absence of any histopathological finding that would account for the trends (such as inflammatory change in any tissue) and the absence a clear dose-response, the variations of leucocyte numbers were considered to represent normal variation and, consequently, were of no biological significance and unrelated to treatment.
There was no histopathological correlate for the slightly low heart weights in males given 330 or 1000 mg/kg/day or the low liver weights in males given 1000 mg/kg/day, and no similar changes were observed in the females, therefore these changes were considered to be fortuitous and of no consequence.
This study included a screen for reproductive/developmental effects and the results obtained were unremarkable. Estrous cycles, pre-coital interval, mating performance, fertility, litter size and gestation length were unaffected by treatment. The clinical condition of the offspring, their survival, growth, sex ratio, ano-genital distance on Day 1 of age and male nipple counts on Day 13 of age showed no adverse effects of parental treatment. There were also no signs in the decedent offspring, or offspring at termination on Day 13 of age that were considered to be related to parental treatment.
The study design also included an assessment of endocrine disruptor relevant endpoints. This objective was met by including the measurement of the hormone thyroxine (T4) in adult males and in offspring at Day 13 of age, by evaluating changes in adult organ weight and gross organ pathology of endocrine-sensitive organs and, because some developmental stages (e.g. gestational and neo-natal) are particularly sensitive to endocrine effects, an external examination of all offspring, measurement of the ano-genital distance of offspring on Day 1 of age and nipple counts for male offspring on Day 13 of age. No adverse effect of treatment was evident on the circulating levels of thyroxine. No significant changes were identified at the microscopic examination of thyroid, adrenal and pituitary glands and the reproductive organs. All offspring were macroscopically normal; in particular no effects were seen on the external genitalia. Ano-genital distances and male nipple counts were not adversely affected by treatment. It was therefore concluded that, in the context of this study, Amidoamine (UVCB) showed no evidence of being an endocrine disruptor.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)